Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ARGX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants… NCT07638566 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy,… Empasiprubart IV | ARGX argenx | Phase 2/3 | Withdrawn was not yet recruiting | 0 | Apr 2028 | Registry ↗ |
| Nov 9, 2026 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP NCT07091630 · Chronic Inflammatory Demyelinating Polyneuropathy, CIDP Empasiprubart IV, Placebo IV | ARGX argenx | Phase 3 | Recruiting | 160 | Oct 7, 2027 | Registry ↗ |
| Nov 5, 2026 | A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations… NCT06078553 · Congenital Myasthenic Syndrome | ARGX argenx | — | Active, not recruiting was recruiting | 152 | Sep 2027 | Registry ↗ |
| Nov 4, 2026 | ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart… NCT07673627 · AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe… Empasiprubart IV, Placebo IV | ARGX argenx | Phase 2 | Recruiting | 40 | Oct 2027 | Registry ↗ |
| Nov 4, 2026 | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis NCT06284954 · Dermatomyositis, Myositis Empasiprubart IV, Placebo IV | ARGX argenx | Phase 2 | Active, not recruiting | 3 | Nov 2026 | Registry ↗ |
| Nov 4, 2026 | A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy NCT05988073 · Multifocal Motor Neuropathy | ARGX argenx | — | Active, not recruiting | 413 | Dec 31, 2028 | Registry ↗ |
| Nov 4, 2026 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod i… NCT04280718 · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Efgartigimod PH20 SC | ARGX argenx | Phase 2 | Active, not recruiting | 229 | Apr 30, 2027 | Registry ↗ |
| Nov 3, 2026 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves… NCT07596849 · Graves Disease efgartigimod PH20 SC, Placebo PH20 SC | ARGX argenx | Phase 3 | Recruiting | 230 | Jun 2028 | Registry ↗ |
| Nov 3, 2026 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves… NCT07570316 · Graves' Disease, Graves Disease Efgartigimod PH20 SC, Placebo PH20 SC | ARGX argenx | Phase 3 | Recruiting | 230 | Jun 2028 | Registry ↗ |
| Nov 3, 2026 | Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study NCT07264426 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy,… Efgartigimod PH20 SC | ARGX argenx | — | Recruiting | 200 | Oct 2029 | Registry ↗ |
| Nov 3, 2026 | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP NCT06920004 · Chronic Inflammatory Demyelinating Polyneuropathy, CIDP empasiprubart, IVIg | ARGX argenx | Phase 3 | Recruiting | 218 | Sep 2027 | Registry ↗ |
| Nov 3, 2026 | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Admini… NCT05374590 · Generalized Myasthenia Gravis, gMG Efgartigimod IV or Efgartigimod PH20 SC | ARGX argenx | Phase 2/3 | Enrolling by invitation | 12 | Sep 2029 | Registry ↗ |
| Oct 29, 2026 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intraven… NCT04833894 · Generalized Myasthenia Gravis Efgartigimod IV | ARGX argenx | Phase 2/3 | Active, not recruiting was recruiting | 15 | Mar 2027 | Registry ↗ |
| Oct 28, 2026 | A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndro… NCT07821762 · Guillain-Barré Syndrome (GBS) Empasiprubart IV, Empasiprubart Placebo IV | ARGX argenx | Phase 2 | Not yet recruiting | 63 | Jan 2028 | Registry ↗ |
| Oct 27, 2026 | A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With… NCT07773727 · Immunoglobulin A Nephropathy (IgAN) ARGX-121, Placebo | ARGX argenx | Phase 2 | Recruiting | 120 | Oct 29, 2029 | Registry ↗ |
| Oct 26, 2026 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple… NCT07294170 · Myasthenia Gravis, MG Efgartigimod IV, Empasiprubart IV | ARGX argenx | — | Recruiting | 70 | Mar 7, 2028 | Registry ↗ |
| Oct 19, 2026 | A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-… NCT07746089 · Congenital Myasthenic Syndrome, CMS Adimanebart IV, Placebo IV | ARGX argenx | Phase 3 | Not yet recruiting | 105 | Oct 2030 | Registry ↗ |
| Oct 19, 2026 | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Pati… NCT04812925 · Primary Immune Thrombocytopenia efgartigimod PH20 SC | ARGX argenx | Phase 3 | Active, not recruiting | 173 | Oct 2027 | Registry ↗ |
| Oct 16, 2026 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic… NCT07194850 · Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia Efgartigimod IV, Placebo IV | ARGX argenx | Phase 2/3 | Recruiting | 24 | Oct 2028 | Registry ↗ |
| Oct 16, 2026 | A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis NCT06655155 · Systemic Sclerosis (SSc) Efgartigimod PH20 SC, Placebo PH20 SC | ARGX argenx | Phase 2 | Active, not recruiting | 87 | Mar 2027 | Registry ↗ |
| Oct 16, 2026 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod i… NCT05979441 · Myositis, Active Idiopathic Inflammatory Myopathy Efgartigimod PH20 SC | ARGX argenx | Phase 3 | Enrolling by invitation | 240 | Sep 2028 | Registry ↗ |
| Oct 14, 2026 | A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syr… NCT07782775 · Healthy Volunteer, Healthy Adult Participants Efgartigimod PH20 SC via PFS, Efgartigimod PH20 SC via AI | ARGX argenx | Phase 1 | Completed | 32 | Sep 23, 2026 | Registry ↗ |
| Oct 14, 2026 | ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function NCT05907096 · Delayed Graft Function ARGX-117, Placebo | ARGX argenx | Phase 2 | Active, not recruiting | 103 | Oct 16, 2025 | Registry ↗ |
| Oct 8, 2026 | A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intra… NCT07287982 · Spinal Muscular Atrophy (SMA) ARGX-119 IV, Placebo IV | ARGX argenx | Phase 2 | Recruiting | 60 | May 28, 2029 | Registry ↗ |
| Sep 28, 2026 | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalize… NCT06392386 · Generalized Myasthenia Gravis Efgartigimod PH20 SC | ARGX argenx | Phase 2/3 | Recruiting | 12 | Sep 2027 | Registry ↗ |
| Sep 24, 2026 | A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Mult… NCT07610564 · Multifocal Motor Neuropathy (MMN) Empasiprubart IV | ARGX argenx | Phase 1 | Recruiting | 60 | Feb 1, 2028 | Registry ↗ |
| Sep 24, 2026 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV… NCT07284420 · AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe… Efgartigimod IV, Empasiprubart IV | ARGX argenx | Phase 2 | Recruiting | 70 | Mar 7, 2028 | Registry ↗ |
| Sep 22, 2026 | A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In… NCT07583641 · Autoimmune Encephalitis (AE) Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC | ARGX argenx | Phase 2 | Not yet recruiting | 170 | Jul 2030 | Registry ↗ |
| Sep 22, 2026 | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Mo… NCT06742190 · Multifocal Motor Neuropathy (MMN), MMN Empasiprubart, IVIG (Intravenous Immunoglobulin) | ARGX argenx | Phase 3 | Active, not recruiting | 154 | Sep 2026 | Registry ↗ |
| Sep 21, 2026 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With A… NCT05523167 · Active Idiopathic Inflammatory Myopathy, Myositis EFG PH20 SC, PBO | ARGX argenx | Phase 2/3 | Completed | 265 | Jul 2, 2026 | Registry ↗ |
| Sep 15, 2026 | A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) NCT06441682 · Amyotrophic Lateral Sclerosis ARGX-119, Placebo | ARGX argenx | Phase 2 | Terminated | 60 | Aug 12, 2026 | Registry ↗ |
| Aug 12, 2026 | A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated S… NCT07760818 · Sjogrens Disease, Primary Sjögren's Syndrome Painful Sensor… efgartigimod PH20 SC, Placebo PH20 SC | ARGX argenx | Phase 2 | Not yet recruiting | 75 | Jul 28, 2028 | Registry ↗ |
| Aug 10, 2026 | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholi… NCT06298552 · Generalized Myasthenia Gravis, gMG Efgartigimod IV, Placebo IV | ARGX argenx | Phase 3 | Active, not recruiting | 119 | Jun 30, 2025 | Registry ↗ |
| Jul 24, 2026 | A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7… NCT06436742 · Congenital Myasthenic Syndrome, CMS ARGX-119, Placebo | ARGX argenx | Phase 1 | Active, not recruiting | 15 | Aug 24, 2027 | Registry ↗ |
| Jul 2, 2026 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Grav… NCT06558279 · Myasthenia Gravis, Ocular Efgartigimod PH20 SC, Placebo PH20 SC | ARGX argenx | Phase 3 | Active, not recruiting | 141 | Jan 12, 2026 | Registry ↗ |
| Jul 2, 2026 | A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe… NCT06503731 · Antibody-mediated Rejection Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC -… | ARGX argenx | Phase 2 | Active, not recruiting | 33 | Nov 2027 | Registry ↗ |
| Jun 29, 2026 | A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Hea… NCT07673601 · Healthy Volunteers (HV), Healthy Volunteer Adimanebart IV, Adimanebart SC - formulation A | ARGX argenx | Phase 1 | Recruiting | 52 | Dec 2026 | Registry ↗ |
| May 28, 2026 | A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjecto… NCT07612020 · Healthy Volunteers empasiprubart SC AI, empasiprubart IV | ARGX argenx | Phase 1 | Recruiting | 130 | Mar 2027 | Registry ↗ |
| May 27, 2026 | An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigim… NCT04980495 · Generalized Myasthenia Gravis, MG - Myasthenia Gravis Efgartigimod IV | ARGX argenx | Phase 3 | Completed | 69 | Aug 24, 2023 | Registry ↗ |
| May 19, 2026 | A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering Fr… NCT07595653 · Generalized Myasthenia Gravis (gMG), gMG | ARGX argenx | — | Recruiting | 100 | Nov 2027 | Registry ↗ |
| May 8, 2026 | A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacody… NCT05225675 · Multifocal Motor Neuropathy ARGX-117, Placebo | ARGX argenx | Phase 2 | Completed | 54 | Jun 4, 2024 | Registry ↗ |
| May 1, 2026 | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Imm… NCT06544499 · Primary Immune Thrombocytopenia (ITP) Efgartigimod IV, Placebo IV | ARGX argenx | Phase 3 | Recruiting | 69 | Jun 2028 | Registry ↗ |
| Apr 23, 2026 | A Study to Assess the Safety of ARGX-213 in Healthy Volunteers NCT06968338 · Healthy Volunteers ARGX-213, Placebo | ARGX argenx | Phase 1 | Completed | 88 | Mar 20, 2026 | Registry ↗ |
| Apr 16, 2026 | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome NCT06684847 · Primary Sjogrens Disease Efgartigimod PH20 SC, Placebo PH20 SC | ARGX argenx | Phase 3 | Active, not recruiting | 631 | Jul 2027 | Registry ↗ |
| Apr 6, 2026 | A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC NCT06637072 · Chronic Inflammatory Demyelinating Polyneuropathy Efgartigimod PH20 SC | ARGX argenx | Phase 4 | Completed | 23 | Feb 19, 2026 | Registry ↗ |
| Mar 24, 2026 | Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Poly… NCT04777734 · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), C… Efgartigimod PH20 SC | ARGX argenx | — | Available | — | — | Registry ↗ |
| Mar 16, 2026 | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. NCT06307626 · Thyroid Eye Disease Efgartigimod PH20 SC, Placebo PH20 SC | ARGX argenx | Phase 3 | Terminated | 105 | Dec 15, 2025 | Registry ↗ |
| Mar 16, 2026 | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease NCT06307613 · Thyroid Eye Disease Efgartigimod PH20 SC, Placebo PH20 SC | ARGX argenx | Phase 3 | Terminated | 102 | Dec 15, 2025 | Registry ↗ |
| Mar 16, 2026 | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary… NCT04225156 · Primary Immune Thrombocytopenia efgartigimod | ARGX argenx | Phase 3 | Completed | 101 | Mar 11, 2026 | Registry ↗ |
| Mar 11, 2026 | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics,… NCT05405361 · Multifocal Motor Neuropathy (MMN) ARGX-117, Placebo | ARGX argenx | Phase 2 | Active, not recruiting | 51 | Sep 30, 2029 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:18 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances